EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Vaso Corp (VASO) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Vaso Corp $0.30, price $0.30, upside +0.0%, quality 63 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · ISIN US92233F1021

VC Vaso Corp logo Thin data Sep 23, 2026

Vaso Corp

VASO · US

NeutralThe stock looks roughly fairly valued with average quality.

·Fair value $0.3000 · Fairly valued (+0%)
!Quality 63/100
!Mixed Growth (revenue 5y +5.0 %/yr)
!Thin margins · 2.0% net margin (TTM)
✓Low debt · generates free cash flow
✓Ranks above peers (11/13)
!Narrow moat 26/100
!Evidence only low, so the estimate is less certain
!Weak on past: 25 out of 100
Watch Vaso Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.3545 $0.0420 Fair Value $0.3000 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range $0.0420 – $0.3545 · fair‑value band $0.2900 – $0.3300 · the $0.3000 price screens below the $0.3000 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 23, 2026.

Follow Vaso in your weekly email

Every Wednesday you see whether Vaso is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Vaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. It operates in three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services.

Show more

Vaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. It operates in three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed network infrastructure, such as routers, switches, and other core equipment; managed network transport; and managed network security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare, Inc. (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging equipment and ultrasound systems, GEHC service agreements, GEHC training, and GEHC and third-party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices and software. This segment offers Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for ECG and blood pressure signals, including cloud-based software and algorithm subscription services; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation therapy systems for non-invasive and outpatient treatment of ischemic heart disease. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. Vaso Corporation was incorporated in 1987 and is headquartered in Plainview, New York.

Stock analysis

Vaso Corp (VASO) currently trades at $0.3000, while our model-based Fair Value estimate is $0.3000, implying the stock looks roughly 0.0% fairly valued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $0.7200 per share, and 14 of the 24 models we run sit above the $0.3000 price.

Bear case: the Asset-Based group reads lowest at $0.1100, and 10 of the 24 models stay below the price. Evidence for this calculation is low.

Scenario range: $0.2900 (bear) to $0.3300 (bull), the price of $0.3000 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 63/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Vaso Corp reported revenue of $89.1M in FY2025 versus $75.6M in FY2021, a compound +4.2%/yr. Reported net income was $1.6M in FY2025, compounding −28.8%/yr from FY2021.

Key figures

Market cap $52.8M · P/E ratio 30.0 · P/S ratio 0.53 · EPS (TTM) $0.0100 · Net margin 1.8% · Return on equity 6.4% · Return on assets (EBIT) 5.2% · Operating margin −6.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).

What moves the price

The share trades about 3% below its 52-week high and 173% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at 0%, VASO screens cheaper than that median.

Fair Value models

Bear $0.2900 Fair Value $0.3000 Bull $0.3300
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.0073 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $0.9200 $1.36 $2.64 77
Growth DCF $0.8800 $1.48 $2.59 76
Owner Earnings $0.3300 $0.4800 $0.8000 75
All 24 models by family
DCF Models
FCF DCF $0.9200 $1.36 $2.64 77
Owner Earnings $0.3300 $0.4800 $0.8000 75
5Y Revenue Exit $0.4800 $0.6000 $0.8200 74
5Y EBITDA Exit $0.5200 $0.6900 $0.9900 75
5Y P/E Exit $0.5100 $0.7200 $0.9600 71
10Y Revenue Exit $0.6000 $0.8300 $1.02 68
10Y EBITDA Exit $0.6400 $0.9100 $1.35 68
10Y P/E Exit $0.6300 $0.9000 $1.31 64
Earnings-Based
Graham-Dodd $0.0600 $0.4200 $0.5900 63
Lynch FV $0.1300 $0.1800 $0.2400 61
PEG = 1.0 $0.1300 $0.1800 $0.2400 57
EPV $0.2800 $0.2900 $0.3000 74
Multiples
P/E Multiple $0.1500 $0.2000 $0.2500 63
P/S Multiple $0.1100 $0.1500 $0.1900 58
P/B Multiple $0.1100 $0.1500 $0.1900 55
EV/EBIT $0.3300 $0.3700 $0.4100 66
EV/EBITDA $0.3500 $0.4100 $0.4600 67
EV/Revenue $0.2900 $0.3300 $0.3700 54
Asset-Based
NCAV (Graham) $0.0800 $0.1100 $0.1700 53
Growth DCF
Growth DCF $0.8800 $1.48 $2.59 76
Rev-Margin DCF $0.4800 $0.6300 $0.8700 73
Economic Profit
Residual Income $0.1300 $0.1300 $0.1200 71
ROIC Compounder $0.2800 $0.2900 $0.3000 72
Growth Earnings
Growth-Adj P/E $0.1800 $0.2500 $0.3300 67

Open the full fair value analysis →

Notify me when VASO reaches fair value

Put VASO on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 63/100

Of which business quality 65 · Market factors (momentum, volatility) 84

Profitability 50
Margins and returns on capital today
Quality Growth 50
Are margins and returns improving?
Cashflow 71
Earnings quality: real cash, not paper profit
Fin. Strength 69
Balance sheet, leverage, solvency risk
Investment 74
Disciplined investing over empire-building
Low Volatility 47
Calm price path (market factor)
Momentum 100
Price trend over the last 3–12 months (market factor)
52W Momentum 98
Distance to the 52-week high (market factor)
Net Issuance 80
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 61/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+2.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.0%
Start year 2020 (pandemic). Over 10 years: +4.6% a year
Revenue growth 36 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.8%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+59.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+59.2%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.34% vs 2%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.1% → 2%
Start year 2020 (pandemic)

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−21.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −23.6% a year for the price.

Watch VASO, get fair value alerts →

Compare Vaso Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 134 stocks

Beats the industry median on 10/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 63 · Above median
Fair Value upside +0% · Above median
Profitability
Return on equity (TTM) 6% · Above median
Return on assets 1% · Above median
Net margin (TTM) 2% · Above median
Operating margin (TTM) −7% · Below median
Growth and dividend
Revenue growth −1% · Below median

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/E (TTM) 30.0× · Cheaper than median
P/B 1.79× · Cheaper than median
P/S (TTM) 0.59× · Cheapest 25%
P/FCF 6.3× · Cheaper than median
EV/EBITDA 6.9× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)33 · sector 3
FUTURE (revenue growth)0 · sector 34
PAST (return on equity)25 · sector 5
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)0 · sector 48

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Veeva Systems Inc VEEV $270.75 $297.83 +10%
Pro Medicus Limited PME A$161.31 A$64.50 −60%
BrightSpring Health Services, Inc BTSG $56.55 $26.07 −54%
HealthEquity, Inc HQY $91.75 $100.93 +10%
Hinge Health, Inc HNGE $94.15 $51.66 −45%
10x Genomics, Inc TXG $80.70 $21.71 −73%
Waystar Holding WAY $25.63 $28.19 +10%
XtalPi Holdings 2228 HK$8.39 HK$1.50 −82%
Doximity, Inc DOCS $26.51 $31.41 +18%
Privia Health Group PRVA $19.46 $5.26 −73%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Vaso Corp · Fair Value
$0.3000 +0%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Vaso Corp Fair Value". https://www.fairvalue-calculator.com/stock/VASO

Frequently asked questions

Is Vaso Corp (VASO) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.3000 versus a price of $0.3000, about +0% upside (fairly valued).
What is the fair value of VASO?
Our model-based fair value for Vaso Corp is $0.3000 (as of Sep 23, 2026), built from audited fundamentals. The current price: $0.3000.
What is the quality score of VASO?
Vaso Corp has a Quality Score of 63/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vaso Corp (VASO)?
Our model-based price target is the fair value of $0.3000 (as of Sep 23, 2026) from 24 valuation models. Cautious scenario $0.2900, optimistic scenario $0.3300. It is a calculation from audited fundamentals, not an analyst target.
What is the Vaso Corp stock forecast for 2026?
Our models put fair value at $0.3000, about +0% upside versus a price of $0.3000 (fairly valued). Cautious scenario $0.2900, optimistic scenario $0.3300. The calculation is refreshed regularly with new filings.
What is the revenue of Vaso Corp (VASO)?
Vaso Corp reported trailing-twelve-month revenue of about $89.0M (latest available figure, as of Sep 23, 2026).
What growth is priced into Vaso Corp (VASO)?
For today's price to be fair in a discounted-cash-flow model, Vaso Corp would have to grow free cash flow by -21.7 % per year for five years (discount rate 8.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +5.0 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of VASO use?
Our models discount Vaso Corp at 8.7 %: a base by market capitalisation (nano), damped by beta 0.57, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Vaso Corp that is -21.7 % per year a year over ten years, using the same discount rate (8.7 %) and the same formula as our fair value.
How much growth has Vaso Corp (VASO) delivered so far?
Over the past 5 years revenue at Vaso Corp grew +5.0 % a year. The price currently implies -21.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Vaso Corp (VASO) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Vaso Corp (-21.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Vaso Corp (VASO)?
The free-cash-flow yield on the price is 15.81 %: that much free cash flow Vaso Corp produces per unit of market value. When it exceeds the discount rate of our models (8.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Vaso Corp (VASO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vaso Corp it is $0.3000 per share (as of Sep 23, 2026), against a price of $0.3000. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Vaso Corp stock overvalued or undervalued in 2026?
As of Sep 23, 2026, VASO trades below its calculated fair value: price $0.3000, fair value $0.3000, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VASO?
No. The price is what the market pays today ($0.3000); the fair value is what the company's own numbers justify ($0.3000). For Vaso Corp the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Vaso Corp worth?
The market values Vaso Corp at about $52.8M (market capitalisation, as of Sep 23, 2026). Per share that is $0.3000; our models calculate a fair value of $0.3000 per share.
What do the bullish and bearish scenarios say about VASO?
Our models span a range for Vaso Corp: cautious scenario $0.2900, base $0.3000, optimistic $0.3300 per share (as of Sep 23, 2026, price $0.3000). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of VASO?
Vaso Corp trades at a price-to-earnings ratio of 30.0 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.3000 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 15.0 (reported for FY2025: 30.0). Other multiples: P/B 1.8, P/S 0.6, EV/EBITDA 6.9.
How solid is the balance sheet of Vaso Corp (VASO)?
Balance-sheet figures for Vaso Corp (as of Sep 23, 2026): return on equity 6.4%. They feed the Quality Score of 63/100, which measures business quality independently of the share price.
How far is VASO from its 52-week high?
Vaso Corp trades at $0.3000, about 3% below its 52-week high of $0.3100 and 173% above the low of $0.1100 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.3000 is for.
Which stocks are comparable to Vaso Corp?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, HealthEquity, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vaso Corp stock attractive at the current price?
The data as of Sep 23, 2026: price $0.3000, calculated fair value $0.3000 (+0%), Quality Score 63/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VASO calculated?
We run Vaso Corp through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.3000, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Vaso Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vaso Corp (VASO)?
The closing price on Sep 23, 2026 was $0.3000. Our model-based fair value is $0.3000, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vaso Corp right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band ($0.2900 to $0.3300), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Vaso Corp

How large is the market capitalisation of Vaso Corp (VASO)?
The market capitalisation of Vaso Corp is $52.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Vaso Corp (VASO)?
The price-to-sales ratio of Vaso Corp is 0.53 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Vaso Corp (VASO)?
Earnings per share at Vaso Corp are $0.0100 (price ÷ EPS = P/E 30.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Vaso Corp (VASO)?
The net margin of Vaso Corp is 1.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Vaso Corp (VASO)?
The return on equity (ROE) of Vaso Corp is 6.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vaso Corp (VASO)?
On an EBIT basis the return on assets of Vaso Corp is 5.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vaso Corp (VASO)?
The operating margin of Vaso Corp is −6.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Vaso Corp (VASO)?
Revenue at Vaso Corp is growing −0.5% versus a year earlier (3y avg +3.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Vaso Corp (VASO)?
Earnings per share at Vaso Corp are growing −47.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Vaso Corp (VASO) hold?
Vaso Corp holds more cash than debt, $10.0M net (fiscal year 2022). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Vaso Corp in the live analysis

One click puts Vaso Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.